Scilex raises $20.3 million through warrant exercise agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
Scilex Holding Company Announces Exercise of Warrants for $20.3 Million Gross Proceeds
November 24, 2025 6:00 AM ESTPALO ALTO, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex or the Company) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of (i) 428,572 shares of common stock (the Common Stock) having an exercise of $38.50 per share and issued in April 2024 (the April 2024 Warrants) and (ii) 475,824 shares of Common Stock having an exercise price of... More
